Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128452 | 0.81 | CHEK1 (0.47) | CHEK1AURKAMAPTSMN1; SMN2EGFR | |
| Methane SCHEMBL10423240 | 0.79 | CHEK1 (0.46) | CHEK1AURKAEGFRCDK1SRC | |
| SCHEMBL868785 | 0.78 | RET (0.39) | EGFRSRCABL1PRKCA | |
| SCHEMBL311873 | 0.76 | CHEK1 (0.52) | CHEK1AURKAEGFRCDK1SRC | |
| SCHEMBL15473878 | 0.76 | YTHDC1 (0.31) | — | |
| SCHEMBL6433606 | 0.76 | — | — | |
| SCHEMBL1128551 | 0.76 | CHEK1 (0.43) | CHEK1AURKAEGFRCDK1SRC | |
| SCHEMBL4725800 | 0.76 | CHEK1 (0.40) | CHEK1AURKASRCABL1 | |
| SCHEMBL29994339 | 0.76 | ERBB2 (0.34) | — | |
| SCHEMBL6431494 | 0.72 | RPS6KB1 (0.46) | CHEK1EGFRSRCABL1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024206895-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024192144-A1 | PYRAZOLOPYRIMIDINES AS ANTIDOTES FOR ARSENICALS | SOUTHERN RESEARCH INSTITUTE (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| EP-4077329-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | Imperial College Innovations Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | CHEK1 1794/4885AURKA 2310/4885LMNA 2458/4885 |
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | DPYD, ABCC1, TYMP | CHEK1 57/4885AURKA 340/4885LMNA 4582/4885 |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | CHEK1 819/4885AURKA 2527/4885LMNA 3033/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | CHEK1 784/4885AURKA 2622/4885LMNA 2445/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | CHEK1 1038/4885AURKA 443/4885LMNA 4664/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | CHEK1 12/4885AURKA 511/4885LMNA 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.